Fig. 2From: Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitorsOverall survival since the readministration of tyrosine kinase inhibitors of patients with short (<6 months), intermediate (6–12 months), and long (>12 months) progression free survival of first-line tyrosine kinase inhibitorsBack to article page